MYRIAD GENETICS INC
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
MYGN$5.67-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
(a)The following documents are included as part of this Annual Report on Form 10-K.
- Financial Statements
See “Index to Consolidated Financial Statements” under Part II, Item 8 to this Annual Report on Form 10-K.
- Financial Statement Schedules
Financial statement schedules have not been included because they are not applicable, or the information is included in financial statements or notes thereto.
- Exhibits
| ExhibitNumber | Exhibit Description | Filed with thisReport | Incorporated byReference hereinfrom Form orSchedule | Filing Date | SEC File/RegistrationNumber |
|---|---|---|---|---|---|
| 3.1 | Restated Certificate of Incorporation, as amended | 10-Q(Exhibit 3.1) | 8/4/2023 | 000-26642 | |
| 3.2 | Restated By-Laws | 8-K (Exhibit 3.1) | 10/15/2020 | 000-26642 | |
| 4.1 | Specimen Common Stock Certificate | 10-K(Exhibit 4.1) | 8/15/2011 | 000-26642 | |
| 4.2 | Description of Securities | 10-KT (Exhibit 4.2) | 3/16/2021 | 000-26642 | |
| Lease Agreements | |||||
| 10.1 | .1 | Lease Agreement, dated February 9, 2022, between Myriad Genetics, Inc. and Bay Bridge/Corporate, LLC | 10-K (Exhibit 10.4.1) | 2/28/2024 | 000-26642 |
| .2 | Second Amendment to Building D Lease Agreement, dated April 10, 2024, between Myriad Genetics, Inc. and ATP SLC D, LLC | 10-K (Exhibit 10.4.2) | 2/28/2025 | 000-26642 | |
| 10.2 | Lease, effective December 7, 2021, between Myriad Women's Health, Inc. and Bayside Area Development, LLC | 10-K (Exhibit 10.5) | 2/28/2024 | 000-26642 | |
| 10.3 | .1 | Lease Agreement, dated December 1, 2012, by and between Assurex Health, Inc. and the City of Mason, Ohio | 10-K (Exhibit 10.6.1) | 2/28/2025 | 000-26642 |
| .2 | Fifth Addendum to Lease Agreement, dated February 20, 2025, between Assurex Health, Inc. and the City of Mason, Ohio | 10-K (Exhibit 10.6.2) | 2/28/2025 | 000-26642 | |
| Agreements with Executive Officers and Directors | |||||
| 10.4 | Non-Employee Director Compensation Policy (effective June 2025)+ | 10-Q (Exhibit 10.4) | 8/6/2025 | 000-26642 | |
| 10.5 | Form of Director and Executive Officer Indemnification Agreement+ | 10-K(Exhibit 10.34) | 8/25/2009 | 000-26642 | |
| 10.6 | Form of Severance and Change in Control Agreement+ | 8-K (Exhibit 10.1) | 10/15/2020 | 000-26642 | |
| 10.7 | Performance-Based Non-Qualified Stock Option Agreement between the Registrant and Paul J. Diaz dated August 13, 2020+ | 10-Q(Exhibit10.4) | 11/9/2020 | 000-26642 | |
| ExhibitNumber · Exhibit Description · Filed with thisReport · Incorporated byReference hereinfrom Form orSchedule · Filing Date · SEC File/RegistrationNumber | ||||
|---|---|---|---|---|
| 10.8 | Non-Qualified Stock Option Agreement between the Registrant and Paul J. Diaz dated August 13, 2020+ | 10-Q(Exhibit10.5) | 11/9/2020 | 000-26642 |
| 10.9 | Consulting Agreement, dated February 24, 2025, by and between the Company and Paul J. Diaz | 8-K(Exhibit 10.5) | 2/24/2025 | 000-26642 |
| 10.10 | Executive Employment Agreement, dated October 17, 2023, between Myriad Genetics, Inc. and Samraat S. Raha+ | 10-Q (Exhibit 10.2) | 11/7/2023 | 000-26642 |
| 10.11 | Chief Operating Officer Severance and Change of Control Agreement, dated December 11, 2023, by and between Myriad Genetics, Inc. and Samraat S. Raha+ | 10-K (Exhibit 10.16) | 2/28/2024 | 000-26642 |
| 10.12 | Amended and Restated Employment Agreement, dated February 24, 2025, between Myriad Genetics, Inc. and Samraat S. Raha+ | 8-K(Exhibit 10.1) | 2/24/2025 | 000-26642 |
| 10.13 | Chief Executive Officer Severance and Change of Control Agreement, dated February 24, 2025, by and between Myriad Genetics, Inc. and Samraat S. Raha+ | 8-K(Exhibit 10.2) | 2/24/2025 | 000-26642 |
| 10.14 | Employment Agreement, dated February 24, 2025, by and between the Company and Mark S. Verratti+ | 8-K(Exhibit 10.3) | 2/24/2025 | 000-26642 |
| 10.15 | Severance and Change of Control Agreement, dated February 24, 2025, by and between the Company and Mark S. Verratti+ | 8-K(Exhibit 10.4) | 2/24/2025 | 000-26642 |
| 10.16 | Restricted Stock Unit Agreement, dated May 1, 2025, by and between the Company and Brian Donnelly+ | 10-Q (Exhibit 10.9) | 5/7/2025 | 000-26642 |
| 10.17 | Performance-Based Restricted Stock Unit Agreement, dated May 1, 2025, by and between the Company and Brian Donnelly+ | 10-Q (Exhibit 10.10) | 5/7/2025 | 000-26642 |
| 10.18 | Separation Agreement and Release of Claims, dated October 1, 2025, by and between the Company and Scott J. Leffler+ | 8-K(Exhibit 10.1) | 10/7/2025 | 000-26642 |
| 10.19 | Executive Employment Agreement, dated August 14, 2025, by and between the Company and Benjamin R. Wheeler+ | 10-Q (Exhibit 10.4) | 11/4/2025 | 000-26642 |
| Equity Compensation Plans | ||||
| 10.20 | 2017 Employee, Director and Consultant Equity Incentive Plan, as amended (June 5, 2025)+ | 8-K(Exhibit 10.1) | 6/5/2025 | 000-26642 |
| 10.21 | Form of Restricted Stock Unit Agreement under the 2017 Equity Incentive Plan (Director)+ | 10-K(Exhibit 10.11) | 8/13/2020 | 000-26642 |
| 10.22 | Form of Restricted Stock Unit Agreement under the 2017 Equity Incentive Plan (Employee)+ | 10-Q (Exhibit 10.1) | 5/4/2023 | 000-26642 |
| 10.23 | Amended and Restated 2012 Employee Stock Purchase Plan+ | 8-K(Exhibit 10.1) | 6/2/2022 | 000-26642 |
| ExhibitNumber | Exhibit Description | Filed with thisReport | Incorporated byReference hereinfrom Form orSchedule | Filing Date | SEC File/RegistrationNumber |
|---|---|---|---|---|---|
| Credit Agreement | |||||
| 10.24 | Credit Agreement, dated July 31, 2025, among Myriad Genetics, Inc., the lenders from time to time party thereto, and Orbimed Royalty and Credit Opportunities IV, LP, as initial lender and administrative agent | 8-K (Exhibit 10.1) | 7/31/2025 | 000-26642 | |
| 10.25 | Pledge and Security Agreement, dated July 31, 2025, among Myriad Genetics, Inc., each of the other Guarantors and Orbimed Royalty and Credit Opportunities IV, LP, as administrative agent for the secured parties | 8-K (Exhibit 10.2) | 7/31/2025 | 000-26642 | |
| 10.26 | First Amendment to Credit Agreement, dated January 5, 2026, among Myriad Genetics Inc., the lenders party thereto, and Orbimed Royalty and Credit Opportunities IV, LP, as administrative agent | X | |||
| Other Exhibits | |||||
| 19 | Insider Trading Policy | 10-K (Exhibit 19) | 2/28/2025 | 000-26642 | |
| 21.1 | List of Subsidiaries of the Registrant | X | |||
| 23.1 | Consent of Independent Registered Public Accounting Firm (Ernst & Young LLP) | X | |||
| 31.1 | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | |||
| 31.2 | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | |||
| 32 | Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | |||
| 97.1 | Clawback Policy | 10-K (Exhibit 97.1) | 2/28/2024 | 000-26642 | |
| 101 | The following materials from Myriad Genetics, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2025, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations (iii) Consolidated Statements of Comprehensive Loss, (iv) Consolidated Statements of Stockholders’ Equity, (v) Consolidated Statements of Cash Flows, and (vi) Notes to Consolidated Financial Statements. Inline XBRL Instance Document – Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | X | |||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | X | |||
(+) Management contract or compensatory plan arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.